Jessica Stendel
Family · Clovis, CANPI 1427042639
Payments from drug & device makers
Across 194 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$987
- AstraZeneca$345
- GSK$322
- Lilly USA, LLC$193
- Pfizer$178
- Biohaven Pharmaceutical Holding Company Ltd.$173
- plus $2K from 26 others
What the payments were for
- Food & beverage$3,839100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 54 | $987 |
| AstraZeneca | 14 | $345 |
| GSK | 19 | $322 |
| Lilly USA, LLC | 11 | $193 |
| Pfizer | 9 | $178 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $173 |
| Boehringer Ingelheim | 9 | $167 |
| Amgen | 8 | $158 |
| Novo Nordisk | 6 | $122 |
| Merck | 6 | $122 |
| Hologic Sales And Service, LLC | 3 | $115 |
| Amarin Pharma, Inc. | 6 | $112 |
| Exact Sciences | 5 | $109 |
| Dynavax Technologies Corporation | 4 | $99 |
| Bayer | 4 | $83 |
| Abbott | 3 | $82 |
| Biohaven Pharmaceuticals, Inc. | 4 | $77 |
| Sanofi Pasteur Inc. | 3 | $54 |
| Ultragenyx Pharmaceutical Inc. | 2 | $45 |
| Lundbeck LLC | 2 | $40 |
| Dexcom, Inc. | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Radius Health, Inc. | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Novartis | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Seqirus USA Inc | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $12 |
How this compares
$3,839 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $21,163 |
| JanuviaSitagliptin Phosphate | 17 | $21,109 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $10,130 |
| Icosapent Ethyl | 26 | $9,462 |
| Wixela InhubFluticasone Propion/Salmeterol | 24 | $3,898 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,571 |
| Rosuvastatin Calcium | 258 | $3,537 |
| Atorvastatin Calcium | 254 | $3,262 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 20 | $3,235 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $3,170 |
| Levothyroxine Sodium | 253 | $2,978 |
| Ezetimibe | 93 | $2,801 |
| Omega-3 Acid Ethyl Esters | 28 | $2,638 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 102 | $2,435 |
| Metoprolol Succinate | 126 | $2,268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $322 | $31,29341 claims |
| MerckJanuvia | $122 | $21,10917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.
Other family in Clovis
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.